Press

Invitation to presentation of Acarix´s second quarter report

22 Aug

Acarix will publish its second quarter results on Thursday 25 August 2022 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.

The webcast will be available at https://www.redeye.se/events/850926/live-q-acarix

The presentation will be available at https://www.acarix.com/for-investors/investor-presentations after publication of the report.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [email protected] 
Christian Lindholm, CFO, phone +46 705 118333, email [email protected]

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [email protected]) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Invitation to presentation of Acarix´s second quarter report

Tags:
,
Newer Acarix AB (publ) publishes Interim Report, January – June 2022
Back to list
Older Samuel Schmidt, Co-founder at Acarix has received the Danish MedTech Society’s Rosenfalck Prize.

Related Posts